Reversing Metabolic Dysfunction-Associated Steatotic Liver Disease Promotes Healthy Pediatric Cardiovascular Structures: The PROC Study-Reference-Cited by-同舟云学术

Reversing Metabolic Dysfunction-Associated Steatotic Liver Disease Promotes Healthy Pediatric Cardiovascular Structures: The PROC Study

Published:2024-05-07 Issue: Volume: Page:
ISSN:0002-9270
Container-title:American Journal of Gastroenterology
language:en
Short-container-title:Am J Gastroenterol

Author:

Li Menglong¹^ORCID,Shu Wen¹,Zou Yuchen¹,Xiao Huidi¹,Asihaer Yeerlin¹^ORCID,Guan Mengying¹,Khattab Nourhan¹^ORCID,Thapa Bipin¹^ORCID,Sapkota Suman¹^ORCID,Vermund Sten H.²^ORCID,Huang Dayong³^ORCID,Hu Yifei¹⁴⁵^ORCID

Affiliation:

1. Department of Child, Adolescent Health and Maternal Care, School of Public Health, Capital Medical University, Beijing, China;

2. Department of Microbiology of Infectious Diseases, Yale School of Public Health, and Department of Pediatrics, Yale School of Medicine, Yale University, New Haven, Connecticut, USA;

3. Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China;

4. UNESCO Chair on Global Health and Education, Peking University, Beijing, China;

5. Beijing Key Laboratory of Environmental Toxicology, Capital Medical University, Beijing, China.

Abstract

INTRODUCTION: We investigated the impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on cardiovascular structure development in children. METHODS: We followed 1,356 children with the mean age of 6.6 years for 4.5 years in Beijing, China. We assessed the association of MASLD with cardiovascular structure (carotid intima-media thickness and left ventricular mass) outcomes at baseline and follow-up. RESULTS: Over follow-up, 59 children had persistent MASLD, 109 had incident MASLD (progression), and 35 had normalization of liver health. Children with MASLD normalization showed a significantly lower mean development in carotid intima-media thickness (0.161 vs 0.188 mm) and left ventricular mass (4.5 vs 12.4 g) than children with persistent MASLD. DISCUSSION: The control of MASLD was associated with improved cardiovascular structure development.

Funder

Capitalâ€™s Funds for Health Improvement and Research

National Natural Science Foundation of China

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference15 articles.

1. A multisociety Delphi consensus statement on new fatty liver disease nomenclature;Rinella;J Hepatol,2023

2. Nonalcoholic fatty liver disease and cardiovascular disease: A review of shared cardiometabolic risk factors;Muzurović;Hypertension,2022

3. Nonalcoholic fatty liver disease and cardiovascular risk: A scientific statement from the American Heart Association;Duell;Arterioscler Thromb Vasc Biol,2022

4. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease;Lee;Gut,2024

5. Usefulness of carotid ultrasound screening in primary cardiovascular prevention: A systematic review;Sebastian;Curr Probl Cardiol,2024